NeuroFrontiers

Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances

Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapy for individuals with generalized myasthenia gravis and its impact on outcomes and steroid reduction in real-world practice. Additional details about MINT may be found in the following publication: The New England Journal of Medicine [https://www.nejm.org/doi/full/10.1056/NEJMoa2501561]. For more information on the medication discussed in this episode, please refer to the Full Prescribing Information [https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/uplizna/uplizna_fpi_english.pdf] provided by Amgen, last updated 12/2025.

The Use of Intracranial Vessel Wall MRI for the Diagnosis of Vasculitis

Jae W. Song, MD, MS, Associate Professor of Radiology at the University of Pennsylvania, Philadelphia, PA, discusses the diagnostic value of intracranial vessel wall MRI for vasculitis, as well as when clinicians should order this imaging technique and the challenges that may arise.

Ocrevus Treatment in Pregnant and Lactating Women with Multiple Sclerosis

Riley Bove, MD, UCSF School of Medicine, San Francisco, CA details results from the MINORE and SOPRANINO studies examining Ocrevus treatment in pregnant and lactating women with multiple sclerosis.

New Guidelines for the Assessment of Traumatic Brain Injury

Beth McQuiston, MD, RD, Medical Director, Abbott, Abbott Park, IL, and David Okonkwo, MD, PhD, Professor of Neurological Surgery, University of Pittsburgh, Pittsburg, PA, describe some of the important updates to guidelines for the assessment of traumatic brain injury, including biomarker testing.

The Impact of High Efficacy DMTs on Paramagnetic Rim Lesions

Jack Reeves, PhD, researcher at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, discusses results of a study which demonstrated high efficacy disease-modifying therapies may help prevent the development of paramagnetic rim lesions and slow the progression of multiple sclerosis.